Quince Therapeutics (QNCX) Common Equity (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Common Equity of $15.7 million for Q1 2026, down 15.66% year-over-year from $18.6 million in Q1 2025, and up 143.88% quarter-over-quarter from -$35.7 million in Q4 2025.
Quince Therapeutics (QNCX) Common Equity (2018 - 2026) Analysis & Trends
Quince Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $15.7 million for Q1 2026.
- In Q1 2026, Common Equity fell 15.66% year-over-year to $15.7 million; the TTM figure through Mar 2026 stood at $15.7 million (down 15.66% YoY), while the FY2025 annual figure was -$35.7 million, down 218.47% from the prior year.
- Common Equity for Q1 2026 stood at $15.7 million, up from -$35.7 million in the prior quarter.
- The five-year high for Common Equity was $111.5 million in Q2 2022, with the low at -$35.7 million in Q4 2025.
- The 5-year median for Common Equity is $74.2 million (2024), against an average of $57.4 million.
- The sharpest annual moves came in 2022 and 2025: Common Equity dropped 15.17% in 2022, then tumbled 218.47% in 2025.
- Quince Therapeutics' Common Equity stood at $100.6 million in 2022, then slipped by 15.42% to $85.1 million in 2023, then sank by 64.57% to $30.1 million in 2024, then sank by 218.47% to -$35.7 million in 2025, then surged by 143.88% to $15.7 million in 2026.
- Business Quant data shows QNCX's Common Equity at $15.7 million in Q1 2026, -$35.7 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | -35.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.67 Mn |
| Dec 31, 2025 | -35.71 Mn |
| Sep 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 11.74 Mn |
| Mar 31, 2025 | 18.58 Mn |
| Dec 31, 2024 | 30.15 Mn |
| Sep 30, 2024 | 44.93 Mn |
| Jun 30, 2024 | 46.97 Mn |
| Mar 31, 2024 | 74.18 Mn |
| Dec 31, 2023 | 85.08 Mn |
| Sep 30, 2023 | 83.13 Mn |
| Jun 30, 2023 | 86.88 Mn |
| Mar 31, 2023 | 90.20 Mn |
| Dec 31, 2022 | 100.59 Mn |
| Sep 30, 2022 | 104.53 Mn |
| Jun 30, 2022 | 111.53 Mn |
| Mar 31, 2022 | 106.38 Mn |
| Dec 31, 2021 | 118.59 Mn |
| Sep 30, 2021 | 132.65 Mn |
| Jun 30, 2021 | 142.08 Mn |